Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Literature
1.
B. Madeo, S. De Vincentis, A. Repaci, P. Altieri, V. Vicennati, E. Kara, F. Vescini, P. Amadori, A. Balestrieri, U. Pagotto, M. Simoni, V. Rochira, The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study. Endocrine 68, 679–687 (2020)CrossRef
2.
R. Eastell, M.L. Brandi, A.G. Costa, P. D’Amour, D.M. Shoback, R.V. Thakker, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3570–3579 (2014)CrossRef
3.
A.A. Khan, D.A. Hanley, R. Rizzoli, J. Bollerslev, J.E. Young, L. Rejnmark, R. Thakker, P. D’Amour, T. Paul, S. Van Uum, M.Z. Shrayyef, D. Goltzman, S. Kaiser, N.E. Cusano, R. Bouillon, L. Mosekilde, A.W. Kung, S.D. Rao, S.K. Bhadada, B.L. Clarke, J. Liu, Q. Duh, E.M. Lewiecki, F. Bandeira, R. Eastell, C. Marcocci, S.J. Silverberg, R. Udelsman, K.S. Davison, J.T. Potts Jr, M.L. Brandi, J.P. Bilezikian, Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int. 28, 1–19 (2017)CrossRef
4.
O.A. Lavryk, A.E. Siperstein, Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J. Surg. 41, 122–128 (2017)CrossRef
5.
Y. Guo, Q. Wang, C. Lu, P. Fan, J. Li, X. Luo, D. Chen, New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study. BMC Endocr. Disord. 20, 5 (2020)CrossRef
6.
P. Cunha-Bezerra, R. Vieira, F. Amaral, H. Cartaxo, T. Lima, U. Montarroyos, F. Bandeira, Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism. J. Med. Imaging Radiat. Oncol. (2018). https://​doi.​org/​10.​1111/​1754-9485.​12728
7.
B. Madeo, S. De Vincentis, E. Kara, F. Vescini, T. Trenti, G. Guaraldi, V. Rochira, Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool in the diagnosis of some Ca-P disorders. J. Endocrinol. Investig. 42, 1041–1049 (2019)CrossRef
Metadata
Title
An analysis of calcium-to-phosphorus ratio in the diagnosis of normocalcemic primary hyperparathyroidism
Author
Pedro Weslley Rosário
Publication date
01-01-2021
Publisher
Springer US
Published in
Endocrine / Issue 1/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02485-0

Other articles of this Issue 1/2021

Endocrine 1/2021 Go to the issue

Original Article

Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations

Original Article

Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms

Original Article

Association of breastfeeding with thyroid function and autoimmunity in postmenopausal women

Original Article

Impact of the COVID-19 pandemic on neuroendocrine tumour services in England

Original Article

Clinical application of a novel next generation sequencing assay for CYP21A2 gene in 310 cases of 21- hydroxylase congenital adrenal hyperplasia from India

Letter to the Editor

Letter to “High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?”
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits